Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck KGaA’s MilliporeSigma to acquire Mirus Bio

by Aayushi Pratap
June 1, 2024 | A version of this story appeared in Volume 102, Issue 17

 

MilliporeSigma, the North American life sciences business of the German company Merck KGaA, has agreed to acquire Mirus Bio for $600 million. Spun off from the University of Wisconsin in 1995, the firm was bought by Wisconsin-based Gamma Biosciences in 2021. Mirus Bio makes transfection reagents, which are used as vehicles to inject viral vector-based gene therapies into cells. The companies expect to complete the deal in the third quarter of this year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.